A carregar...

Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice

BACKGROUND: Nalfurafine is the first clinically approved kappa-opioid receptor (KOP-r) agonist as an anti-pruritus drug with few side effects in humans (e.g., sedation, depression and dysphoria). No study, however, has been done using nalfurafine on alcohol drinking in rodents or humans. METHODS: We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alcohol Clin Exp Res
Main Authors: Zhou, Yan, Kreek, Mary Jeanne
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551307/
https://ncbi.nlm.nih.gov/pubmed/30908671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acer.14033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!